Midodrine

Generic Name: Midodrine

Brand Names: Proamatine

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₈N_₂O_₄

CAS Number: 42794-76-3

Unique Ingredient Identifier: 6YE7PBM15H

Background: An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension.

Indication: For the treatment of symptomatic orthostatic hypotension (OH).

Associated Conditions: Symptomatic Orthostatic Hypotension

Associated Therapies: -

Clinical Trials

An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty

Not Applicable

Terminated

Conditions: Orthostatic Hypotension

Interventions: Drug: Midodrine
Other: Intravenous fluid bolus

First Posted Date: 2014-06-03

Last Posted Date: 2017-07-31

Lead Sponsor: Hospital for Special Surgery, New York

Target Recruit Count: 13

Registration Number: NCT02154243

Locations: 🇺🇸
Hospital for Special Surgery, New York, New York, United States

Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty

Phase 3

Completed

Conditions: Postoperative Orthostatic Hypotension
Postoperative Orthostatic Intolerance

Interventions: Drug: Placebo
Drug: Midodrine

First Posted Date: 2012-10-16

Last Posted Date: 2014-01-20

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 120

Registration Number: NCT01707953

Locations: 🇩🇰
Gentofte Hospital, Department of orthopaedic surgery, Hellerup, Denmark
🇩🇰
Hvidovre Hospital, Department of orthopaedic surgery, Hvidovre, Denmark
🇩🇰
Vejle Sygehus, Department of orthopedic surgery, Vejle, Denmark

Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure

Phase 2

Withdrawn

Conditions: Fibrosis
Renal Failure
Hepatorenal Syndrome

Interventions: Drug: Albumin
Drug: Midodrine
Drug: Octreotide

First Posted Date: 2012-04-30

Last Posted Date: 2019-02-15

Lead Sponsor: Anna Cruceta

Registration Number: NCT01587222

Locations: 🇪🇸
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

Midodrine for the Treatment of Refractory Hypotension

Phase 3

Completed

Conditions: Critical Illness
Hypotension

Interventions: Drug: Placebo
Drug: Midodrine

First Posted Date: 2012-02-13

Last Posted Date: 2020-10-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 139

Registration Number: NCT01531959

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension

Phase 4

Completed

Conditions: Orthostatic Hypotension

Interventions: Drug: Placebo
Drug: Midodrine HCl

First Posted Date: 2012-01-26

Last Posted Date: 2021-06-08

Lead Sponsor: Shire

Target Recruit Count: 24

Registration Number: NCT01518946

Locations: 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸
Advance Research Institute Inc, New Port Richey, Florida, United States
🇺🇸
Kidney and Hypertension Center, Roseburg, Oregon, United States

and more 10 locations

Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension

Phase 4

Completed

Conditions: Symptomatic Orthostatic Hypotension

Interventions: Drug: Placebo
Drug: Midodrine HCl

First Posted Date: 2012-01-24

Last Posted Date: 2021-06-09

Lead Sponsor: Shire

Target Recruit Count: 98

Registration Number: NCT01515865

Locations: 🇺🇸
PAREXEL International - Baltimore EPCU Harbor Hospital, Baltimore, Maryland, United States
🇨🇿
Fakultní nemocnice v Motole, Praha, Czechia
🇸🇰
Neurologické oddelenie FNsP Žilina, Fakultná nemocnica s poliklinikou Žilina, Žilina, Slovakia

and more 29 locations

Blood Pressure and Brain Blood Flow Regulation After Midodrine Administration in Those With Spinal Cord Injury

Completed

Conditions: Orthostatic Intolerance

First Posted Date: 2011-12-23

Last Posted Date: 2019-10-01

Lead Sponsor: University of British Columbia

Target Recruit Count: 22

Registration Number: NCT01498809

Locations: 🇨🇦
GF Strong Hospital and Rehabilitation Centre, Vancouver, British Columbia, Canada

Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis

Not Applicable

Withdrawn

Conditions: Cirrhosis
Ascites
End Stage Liver Disease
Hypotension

Interventions: Drug: Midodrine

First Posted Date: 2011-04-08

Last Posted Date: 2013-07-31

Lead Sponsor: The Cleveland Clinic

Registration Number: NCT01331785

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation

Phase 4

Completed

Conditions: Renal Failure
Hepatic Encephalopathy
Hyponatremia
Sepsis
Gastrointestinal Bleeding

Interventions: Drug: albumin
Drug: Placebo
Drug: Midodrine

First Posted Date: 2009-02-09

Last Posted Date: 2016-08-18

Lead Sponsor: Hospital Clinic of Barcelona

Target Recruit Count: 199

Registration Number: NCT00839358

Locations: 🇪🇸
Hospital Clinic, Villarroel 170, Barcelona, Spain

Safety and Efficacy of L-NAME and Midodrine to Increase MAP

Phase 2

Completed

Conditions: Orthostatic Hypotension
Spinal Cord Injury

Interventions: Drug: Placebo
Drug: Midodrine
Drug: L-NAME

First Posted Date: 2009-02-03

Last Posted Date: 2014-04-23

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 34

Registration Number: NCT00835224

Locations: 🇺🇸
VA Medical Center, Bronx, Bronx, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy